Start
Entdecken
nav.journalClub
Trends
Mehr
Synapse
⌘+K
Synapse
Sprache
Deutsch
Deutsch
September 16, 2025
View Full Paper
Table S2. from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer
RY
Rona Yaeger
Memorial Sloan Kettering Cancer Center
JM
Jean-François Martini
Pfizer (United States)
LP
Lincoln W. Pasquina
Boston Foundation
See all
Key Points
The effectiveness of FoundationOne Liquid CDx for detecting BRAF V600E was validated in colorectal cancer cases.
Plasma samples sourced from diverse groups help ensure reliability in BRAF V600E detection.
Sample sizes and attributes from testing are crucial for validating clinical applications of the liquid biopsy technology.
This assessment highlights the importance of robust liquid biopsy methodologies in oncology diagnostics.
Abstract
Plasma sample sizes and sources for LBx testing.
KI fragen
Mark Helpful
Like
Save
Bookmark
Relay
Share
View Full Paper
KI fragen
Mark Helpful
Like
Save
Bookmark
Relay
Share
View Full Paper
Cite This Study
Copy
Yaeger et al. (Tue,) studied this question.
synapsesocial.com/papers/68d4565b31b076d99fa5b1a4
https://doi.org/https://doi.org/10.1158/2767-9764.30083886
Table S2. from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer | Synapse